<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>Form 424B5 - Prospectus [Rule 424(b)(5)]</title>
<style>
body { font-family: Arial, Helvetica, sans-serif; background:#0f1115; color:#e6e6e6; margin:0; padding:40px; }
.container { max-width:700px; margin:auto; background:#161a21; border-radius:10px; padding:32px; box-shadow:0 0 30px rgba(0,0,0,0.4); }
h1 { margin-top:0; color:#4da3ff; }
table { width:100%; margin-top:12px; border-collapse:collapse; }
th, td { text-align:left; padding:6px 8px; border-bottom:1px solid #2a2f3a; }
ul { margin-top:12px; padding-left:20px; }
.section { margin-top:24px; }
.small { margin-top:12px; font-size:13px; color:#999; }
a { color:#4da3ff; }
</style>
</head>
<body>
  <div class="container">
    <h1>Form 424B5 - Prospectus [Rule 424(b)(5)]</h1>

    <table>
      <tr><th>Ticker</th><td>STRO</td></tr>
      <tr><th>Float</th><td>N/A</td></tr>
      <tr><th>IO</th><td>N/A</td></tr>
      <tr><th>MC</th><td>N/A</td></tr>
      <tr><th>Extra Info</th><td>None</td></tr>
    </table>

    <div class="section">
      <strong>Summary</strong>
      <p>Sutro Biopharma, Inc. (CIK: 0001382101) filed a Form 424B5 prospectus with the SEC on 2026-02-10 (Accession No. 0001193125-26-044923) relating to Registration Statement File No. 333-275525. The SEC index lists three submission files, including the primary 424B5 HTML document (d72308d424b5.htm, 392,028 bytes) and two graphic files. Company address: 111 Oyster Point Blvd., South San Francisco, CA 94080; phone: 650-392-8412. The index page itself does not disclose offering terms, security amounts, pricing, or underwriters — those details are contained in the primary 424B5 document.</p>
    </div>

    <div class="section">
      <strong>Positives</strong>
      <ul><li>Company submitted a Form 424B5 prospectus, indicating an active, updated registration statement (File No. 333-275525).</li><li>Primary prospectus document is available on the SEC EDGAR site (d72308d424b5.htm).</li></ul>
    </div>

    <div class="section">
      <strong>Negatives</strong>
      <ul><li>SEC index page does not include the offering size, securities type, pricing, or underwriting terms.</li><li>Index alone lacks investor-level terms; the full 424B5 document must be reviewed for material offering details.</li></ul>
    </div>

    <div class="section">
      <a href="https://www.sec.gov/Archives/edgar/data/1382101/000119312526044923/0001193125-26-044923-index.htm" target="_blank">Original Article</a>
    </div>

    <div class="small">STRO • TradersLink AI News</div>
  </div>
</body>
</html>